4DMT is focused on the discovery and development of targeted, customized and proprietary next-generation AAV gene therapy products for use in patients with severe genetic diseases with high unmet medical need. Their robust discovery platform, termed Therapeutic Vector Evolution, empowers the company to create customized gene delivery vehicles to deliver genes specifically to any tissue or organ in the body, by optimal clinical routes of administration, at lower doses and with resistance to pre-existing antibodies. These proprietary and targeted products allow 4DMT to treat both rare genetic diseases and complex large market diseases.
4D Molecular Therapeutics
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.